周五，伯恩斯坦分析师强调了GLP-1药物在应对全球肥胖流行中的重要作用，特别强调了诺和诺德公司的Wegovy和礼来的Zepbound目前在市场上的主导地位。礼来市值超过7050亿美元，过去12个月收入增长27%，是这个不断扩大的市场中的重要参与者。

Stock Editorial via Getty Images An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has ...

Ro, a telehealth company, has teamed up with Eli Lilly to improve patient access to Zepbound (tirzepatide). Through ...

Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...

Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand.

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...

Direct-to-consumer health startup Ro has partnered with Eli Lilly to provide more affordable single-dose vials of the ...

Eli Lilly has partnered with the telehealth company Ro to expand access to single-dose vials of its popular weight loss drug Zepbound. Through Ro's platform, eligible patients can receive ...

Eli Lilly partners with telehealth company Ro to distribute discounted Zepbound vials at $399/month, while competitor Novo ...

Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) ...

Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...

Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss ...